The stock of Johnson & Johnson (NYSE:JNJ) decreased by -$1.96 on Monday to finish at $164.29, down -1.18 percent. The last five days have seen an average of 56,649,020 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$12.36. The average number of shares traded over the last 20 days was 52,355,801, while the average volume over the last 50 days totaled 26,458,000.
JNJ stock dropped -5.84% since last month. On 08/28/23, the company’s shares reached a one-month low of $163.16. The stock touched a high of $181.04 on 01/06/23, after rallying from a low of $150.11 in 52 weeks. The price of JNJ stock has declined by -7.00% or -$12.36 this year, reaching a new high 3 times. Still, the stock price is down -9.25% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
JNJ stock investors should be aware that Johnson & Johnson (JNJ) stock had its last reported insider trading activity 34 days ago on Jul 26. On Jul 26, Hait William sold 14,698 shares at $172.00 each. This transaction resulted in the insider making $2,528,056. On Jul 25, Fasolo Peter sold 20,000 shares at a price of US$170.32. After the transaction, the insider now owns 102,696 shares. EVP, Chief TO and Risk Officer Wengel Kathryn E had earlier sold 12,465 shares on Jun 12 for $160.00 a share. The transaction was completed for $1,994,400.
Valuation Metrics
Johnson & Johnson (JNJ) has a trailing price-to-earnings (P/E) ratio of 33.29. Beta for the stock is 0.54. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.02, the price-to-book (PB) ratio of 5.68, and the price-to-cash flow ratio of 27.01.
Company paid $1.19 per share in dividends, remained unchanged from $1.19 last year. A $0.06 dividend increase was reported on Tuesday April 18 2023.
Financial Health
For the three months ended June 29, Johnson & Johnson’s quick ratio was 0.90, while its current ratio was 1.10, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.45, and the total debt to equity ratio is 0.61. As far as profitability goes, gross margin for the trailing twelve months is 67.20% percent. Johnson & Johnson’s EBITDA margin for the year ended June 29 was 33.42%, whereas its operating margin stood at 16.40% for the same period. Based on annual data, it had gross profit of $63.85 billion and revenue of $94.94 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. JNJ’s return on assets (ROA) during the last 12 months has been 7.00%. There was a 15.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 17.60%.
Earnings Surprise
According to Johnson & Johnson’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $25.53 billion, while revenues rose by 5.91% to $24.75 billion. It was predicted that Johnson & Johnson’s quarterly earnings would be $2.59, but it ended up being $2.42, beating the consensus by 7.00%. EBITDA was $9.41 billion for the quarter. At the end of Johnson & Johnson’s most recent quarter ended June 29, its liabilities totaled 115.28 billion, while its total debt was $45.6 billion. Equity owned by shareholders amounts to $2.6 billion.
Technical Picture
Here’s a quick look at Johnson & Johnson’s (JNJ) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 33.13%, suggesting the stock is Neutral, with a 16.73% historical volatility rate.
The stochastic %K and %D were 14.66% and 12.76% respectively, while the average true range (ATR) was 3.25. Based on the 14-day stochastic reading of 8.79%, the RSI (14) reading is 39.69%. On the 9-day MACD Oscillator, the stock is at -2.84, and the 14-day reading is at -4.64.
Analyst Ratings
Analysts have assigned Johnson & Johnson (JNJ) an Overweight rating. JNJ is a stock that is recommended for selling by 0 brokerage firms, while 14 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 2 rates it overweight and 6 others recommend it as a buy.
What is JNJ’s price target for the next 12 months?
The current consensus forecast for the stock is between $167.00 and $215.00, with a median target price of $181.00. In analyzing these forecasts, the average price target given by analysts for Johnson & Johnson (JNJ) is $183.53.
